Datacubed Health’s mobile platform has been selected to support studies for those at risk of Dominantly Inherited Alzheimer’s Disease, a rare form of early-onset Alzheimer’s Disease. The Linkt platform enables the collection of real-time data on sleep, diet and other biomarkers using a “bring your own device” (BYOD) study model.
Datacubed Health’s app, platform and web-based portal will be used by scientists at the Dominantly Inherited Alzheimer Network (DIAN) at the Washington University School of Medicine in Saint Louis. The DIAN research incorporates an observational study, clinical drug trials, a research registry and smaller ancillary studies.
The app and portal utilize a gamified experience with rewards for completion and compliance. Participants navigate an interactive map journey creating variable rewards such as digital gems and visual progress as they complete articles, surveys and tasks. Datacubed Health’s tools allow researchers and study coordinators to enroll participants, monitor real-time progress and compliance dashboards, manage incentives and review study data.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.